Not Yet Recruiting PHASE4 INTERVENTIONAL 3-arm
NCT07073053
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
Sponsor: Taipei Veterans General Hospital, Taiwan
Conditions
Coronary Arterial Disease (CAD) Glucagon-Like Peptide-1 Receptor Agonists Type 2 Diabetes
Interventions
Semaglutide 0.5 mg Semaglutide 1.0 mg
Updated 2 times since 2025 Last updated: Jul 9, 2025 Started: Oct 1, 2025 Primary completion: Jul 31, 2028 Completion: Jul 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE4 clinical study on Coronary Arterial Disease (CAD) and Glucagon-Like Peptide-1 Receptor Agonists, this trial is actively recruiting participants. The trial is conducted by Taipei Veterans General Hospital, Taiwan and has accumulated 2 data snapshots since 2025. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
2 versions recorded-
Jan 2026 — Present [monthly]
Not Yet Recruiting PHASE4
-
Aug 2025 — Present [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Taipei Veterans General Hospital, Taiwan
Data source: Taipei Veterans General Hospital, Taiwan
For direct contact, visit the study record on ClinicalTrials.gov .